logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Bioatla, Inc.

Calculating rank
USPTO Granted Patents = 50

% Expired Patents = 2.0



Forward Citations = 62

Loading Chart...
Loading Chart...

9 inventors (with patents filed for the assignee):

goldMedal Jay Milton Short (48 out of 179 patents)

silverMedal Hwai Wen Chang (32 out of 58 patents)

bronzeMedal Gerhard Johann Frey (32 out of 87 patents)

4.  Gregory Ian Frost (2 out of 8 patents)

5.  James Joseph Onuffer, Jr (2 out of 7 patents)

6.  Richard A Miller (2 out of 25 patents)

7.  Emily Piccione Griffin (2 out of 7 patents)

8.  William James Boyle (2 out of 30 patents)

9.  Anirban Kundu (1 out of 1 patent)


Core Competencies:
Chimeric Antigen Receptors
Monoclonal Antibodies
Anti-CTLA4 Antibodies
Protein Evolution
Anti-EpCAM Antibodies
Conditionally Active Proteins
Multi-Specific Antibodies
Humanized Antibodies
Anti-AXL Antibodies
Diagnostics
Antibody Fragments
Mirac Proteins

50 patents:

1. 12742020 - CHIMERIC ANTIGEN RECEPTORS TO HER2 AND METHODS OF USE THEREOF (2026-09-22),
2. 12649793 - ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof (2026-06-09),
3. 12631650 - PROTEINS TARGETING ORTHOLOGS (2026-05-19),
4. 12595592 - Comprehensive monoclonal antibody generation (2026-04-07),
5. 12473360 - MULTI-SPECIFIC ANTIBODY CONSTRUCTS (2025-11-18),
6. 12427347 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2025-09-30),
7. 12187801 - Chimeric antigen receptors against AXL or ROR2 and methods of use thereof (2025-01-07),
8. 12110611 - Conditionally active biological proteins (2024-10-08),
9. 11976381 - Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts (2024-05-07),
10. 11897959 - Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof (2024-02-13),
11. 11879011 - Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof (2024-01-23),
12. 11859007 - Humanized anti-CD73 antibodies (2024-01-02),
13. 11851499 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-26),
14. 11834472 - Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-05),
15. 11773509 - Conditionally active polypeptides and methods of generating them (2023-10-03),
Company Overview
Bioatla, Inc. is a biotechnology company based in San Diego, California, specializing in advanced antibody engineering. The company focuses on the development of innovative therapeutic solutions, particularly in the realm of cancer treatment. Bioatla's core technologies include chimeric antigen receptors, monoclonal antibodies, and conditionally active proteins, which are designed to enhance the efficacy and specificity of immune responses. Their research encompasses multi-specific and humanized antibodies, aiming to address complex medical challenges in oncology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Bioatla, Inc. USPTO Patent Assignee Logo
50 Patents

#124 in San Diego, CA

#1,652 in California

#7,020 in US

#14,027 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Bioatla, Inc.

Forward Citations = 62

9 inventors:

goldMedal Jay Milton Short (48 out of 179 patents)

silverMedal Hwai Wen Chang (32 out of 58 patents)

bronzeMedal Gerhard Johann Frey (32 out of 87 patents)

4.  Gregory Ian Frost (2 out of 8 patents)

5.  James Joseph Onuffer, Jr (2 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bioatla, Inc.. Retrieved from https://idiyas.com/company/bioatla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…